Use of random versus apheresis platelet concentrates

Transfusion Clinique et Biologique

Volumn 14, Issue 6, 2007, Pages 514-521

  Andreu, G ^a   Vasse, J ^b   Sandid, I ^c   Tardivel, R ^b   Semana, G ^b  

^a INSTITUT NATIONAL DE LA TRANSFUSION SANGUINE   (France)

^b ETS de Bretagne   (France)

^c AFSSAPS   (France)

Author keywords

Adverse reaction; Apheresis; Platelet; Use

Indexed keywords

HEMOGLOBIN; THROMBOCYTE CONCENTRATE;

APHERESIS; ARTICLE; BACTERIUM CONTAMINATION; BLOOD DONOR; DISEASE TRANSMISSION; ERYTHROCYTE; HEALTH SERVICE; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HLA SYSTEM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNIZATION; INTERMETHOD COMPARISON; PATIENT CARE; RISK FACTOR; THROMBOCYTE FUNCTION;

ADULT; BLOOD PLATELETS; BLOOD PRESERVATION; HEPATITIS B; HEPATITIS C; HIV INFECTIONS; HUMANS; PLATELET COUNT; PLATELET TRANSFUSION; PLATELET-RICH PLASMA; PLATELETPHERESIS;

EID: 43049110550     PISSN: 12467820     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tracli.2008.01.004     Document Type: Article

References (47)

1. Freireich E.J., Kliman A., Gaydos L.A., et al. Response to repeated platelet transfusion from the same donor. Ann Intern Med 59 (1963) 277-287
2. Mourad N. A simple method for obtaining platelet concentrates free of aggregates. Transfusion 8 (1968) 48
3. McCredie K.B., Freireich E.J., Hester J.P., and Vallejos C. Leukocyte transfusion therapy for patients with host-defense failure. Transplant Proc 5 3 (Sep 1973) 1285-1289
4. Ts'ao C.H., Wirman J.A., and Ruder E.A. Altered in vitro functions of platelets prepared by the haemonetics blood processor. J Lab Clin Med 86 2 (Aug 1975) 315-325 Links
5. Pietersz R.N., Reesink H.W., Dekker W.J., and Fijen F.J. 1: preparation of leukocyte-poor platelet concentrates from buffy coats. II. Lack of effect on storage of different plastics. Vox Sang 53 4 (1987) 208-213
6. Murphy S. Platelets from pooled buffy coats: an update. Transfusion 45 (2005) 634-639
7. Van der Poel C. The use of labile blood components in relation to optimal use and risk. EuroSAT meeting, Paris, October 4, 2007.
8. Sloand E.M., Yu M., and Klein H.G. Comparison of random-donor platelet concentrates prepared from whole blood units and platelets prepared from single-donor apheresis collections. Transfusion 36 (1996) 955-959
9. Turner V.S., Hawker R.J., Mitchell S.G., and Symour Mead A.M. Paired in vivo and in vitro comparison of apheresis and "recovered" platelet concentrates stored for 5 days. J Clin Apheresis 9 (1994) 189-194
10. Eernisse J.G., and Brand A. Prevention of platelet refractoriness due to HLA antibodies by administration of leukocyte-poor blood components. Exp Hematol 9 1 (Jan 1981) 77-83
11. Andreu G., Dewailly J., Leberre C., Quarre M.C., Binet M.L., Tardivel R., et al. Prevention of HLA immunization with leukocyte-poor packed red cells and platelet concentrates obtained by filtration. Blood 72 3 (1988) 964-969
12. Ness P.M., and Campbell-Lee S.A. Single donor versus pooled random donor platelet concentrates. Curr Opin Hematol 8 (2001) 392-396
13. Ness P., Braine H., King K., et al. Single-donor platelets reduce the risk of septic platelet transfusion reactions. Transfusion 41 (2001) 857-861
14. Piertersz R.N., de Korte D., Reesink H.W., et al. Preparation of leukocyte-poor platelet concentrates from buffy-coats. III. Effect of leukocyte contamination on storage conditions. Vox Sang 55 (1988) 14-20
15. Bertolini F., Rebulla P., Porretti L., and Murphy S. Platelet quality after 15 day storage of platelet concentrates prepared from buffy coats and stored in a glucose-free crystalloid medium. Transfusion 32 (1992) 9-16
16. Fijnheer, Pietersz R.N.I., de Korte D., et al. Platelet activation during preparation of platelet concentrates: a comparison of the platelet-rich plasma and the buffy coat methods. Transfusion 30 (1990) 634-638
17. 51 Cr. Transfusion 32 (1992) 113-120
18. Muylle L., Wouters E., and Peetermans M.E. Febrile reactions to platelet transfusion: the effect of increased interleukin 6 levels in concentrates prepared by the platelet-rich plasma method. Transfusion 36 10 (1996) 886-890
19. Oksanen K., Ebeling F., Kekomaki R., Elonen E., Sahlstedt L., Volin L., et al. Adverse reactions to platelet transfusions are reduced by use of platelet concentrates derived from buffy coat. Vox Sang 67 (1994) 356-361
20. Anderson N.A., Gray S., Copplestone J.A., et al. A prospective randomized study of three types of platelet concentrates in patients with haematological malignancy: corrected platelet increments and frequency of non haemolytic febrile transfusion reactions. Transfus Med 7 (1997) 33-39
21. Chaudhary R., Aggarwal A., Khetan D., and Dayal R. Cytokine generation in stored platelet concentrate: comparison of two methods of preparation. Indian J Med Res 124 (2006) 427-430
22. Larsson S., Sandgren P., Sjodin A., et al. Automated preparation of platelet concentrates from pooled buffy coats: in vitro studies and experiences with the OrbiSac system. Transfusion 45 (2005) 743-751
23. Strindberg J., and Berlin G. Transfusion of platelet concentrates - clinical evaluation of two preparations. Eur J Haematol 57 (1996) 307-311
24. Ericksson L., Kristensen J., Olsson K., et al. Evaluation of platelet function using the in vitro bleeding time and corrected count increment of transfused platelets. Comparison between platelet concentrates derived from pooled buffy coats and apheresis. Vox Sang 70 (1996) 69-75
25. Akkök C.A., Brinch L., Lauritzsen G.F., Solheim B.G., and Kjeldsen-Kragh J. Clinical effect of buffy-coat vs. apheresis platelet concentrates in patients with severe thrombocytopenia after intensive chemotherapy. Vox Sang 93 1 (Jul 2007) 42-48
26. Vasse J, Tardivel R, Gaucheron S, Andreu G, Semana G. Surveillance study of the transfusion efficiency after transfusions of apheresis platelet concentrates and pooled platelet concentrates. ISBT regional meeting, Madrid, July 7, 2007.
27. Arnold D.A., Heddle N.M., Kulczycky M., et al. In vivo recovery and survival of apheresis and whole blood-derived platelets: a paired comparison in healthy adults. Transfusion 46 (2006) 257-264
28. Gurkan E., Patah P.A., Saliba R.M., Ramos C.A., Anderson B.S., Champlin R., et al. Efficacy of prophylactic transfusions using single donor apheresis platelets versus pooled platelet concentrates in AML/MDS patients receiving allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant (2007) 1-4
29. The Trial to Reduce Alloimmunization to Platelets Study Group. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Engl J Med 337 (1997) 1861-1869
30. Pillonel J., Le Marrec N., Girault A., David D., and Laperche S. Epidemiological surveillance of blood donors and residual risk of blood-borne infections in France, 2001 to 2003. Transfus Clin Biol 12 3 (Jul 2005) 239-246 Links
31. Rebibo D., Hauser L., Zorzi P., Legras J.F., Afssaps, Slimani A., et al. International forum: hemovigilance. Vox sang 90 3 (2006) 207-241
32. Högman C.F., Gong J., Eriksson L., Hambraeus A., and Johansson C.S. White cells protect donor blood against bacterial contamination. Transfusion 31 7 (Sep 1991) 620-626
33. Andreu G., and Dewailly J. Prevention of HLA alloimmunization by using leukocyte-depleted components. Curr Stud Hematol Blood Transfus (1994) 29-40
34. Enright H., Davis K., Gernsheimer T., McCullough J.J., Woodson R., and Slichter S.J. Factors influencing moderate to severe reactions to PLT transfusions: experience of the TRAP multicenter clinical trial. Transfusion 43 (2003) 1545-1552
35. Gulliksson H., AuBuchon J.P., Cardigan R., et al. Storage of platelets in additive solutions: a multicentre study of the in vitro effects of potassium and magnesium. Vox Sang 85 (2003) 199-205
36. Kerkhoffs J.L., Eikenboom J.C., Schipperus M.S., van Wordragen-Vlaswinkel R.J., Brand R., Harvey M.S., et al. A multicenter randomized study of the efficacy of transfusions with platelets stored in platelet additive solution II versus plasma. Blood 108 (2006) 3210-3215
37. de Wildt-Eggen J., Nauta S., Schrijver J.G., van Marwijk Kooy M., Bins M., and van Prooijen H.C. Reactions and platelets increments after transfusion of platelet concentrates in plasma or an additive solution: a prospective, randomised study. Transfusion 40 (2000) 398-403
38. Snyder E., McCullough J., Slichter S.J., Strauss R.G., Lopez-Plaza I., Lin J.S., et al. Clinical safety of platelets photochemically treated with amotosalen HCl and ultraviolet A light for pathogen inactivation: the SPRINT trial. Transfusion 45 (2005) 1864-1875
39. Andreu G., Vasse J., Herve F., Tardivel R., and Semana G. Introduction of platelet additive solutions in transfusion practice. Advantages, disadvantages and benefit for patients. Transfus Clin Biol 14 (2007) 100-106
40. Rebibo D., Simonet M., and Slimani A. Étude nationale sur les effets indésirables receveurs liés aux concentrés de plaquettes avec et sans solution de conservation. Transfus Clin Biol 14 (2007) 213-214
41. Andreu G., Morel P., Forestier F., Debeir J., Rebibo D., Janvier G., et al. Haemovigilance network in France: organization and analysis of immediate transfusion incident reports from 1994 to 1998. Transfusion 42 (2002) 1356-1364
42. Llewelyn C.A., Hewitt P.A., Knight R.S.G., Amar K., Cousens S., Mackenzie J., et al. Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet 363 (2004) 417-421
43. Alpérovitch A, Barin F, Bégaud B, Béloucif S, Billette de Villemeur T, Brown P, et al. Analyse du risque de transmission de la nouvelle variante de la maladie de Creutzfeldt-Jakob par le sang et ses dérivés. Recommandations, Agence française de sécurité sanitaire des produits de santé, 11 décembre 2000.
44. Brown P., Rohwer R.G., Dunstan B.C., MacAuley C., Gajdusek D.C., and Drohan W.N. The distribution of infectivity in blood components and plasma derivatives in experimental models of transmissible spongiform encephalopathy. Transfusion 38 (1998) 810-816
45. Chabanel A., Carrat F., Begue S., Masse M., Perrault M.P., and Andreu G. Quality of leucoreduced red blood cell concentrates: 5 years of follow-up in France. Vox Sang 97 (2008) 41-47
46. Winters J.L. Complications of donor apheresis. J Clin Apheresis 21 2 (Jul 2006) 132-141
47. Rebibo D., Hauser L., Simonet M., and Slimani A. Hémovigilance donneur : aspects nationaux et internationaux. Transfus Clin Biol 14 (2007) 173